Friday Feb 10 | GlobeNewswire
Endologix to Report Fourth Quarter and Full Year 2011 Financial Results on February 22, 2012
Endologix, Inc. , developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2011 financial results, which will take place on Wednesday, February 22, 2012 after the close of the market.
Endologix Announces First Patient Treated in Ventana(TM) U.S. Clinical Trial
Endologix, Inc. announced today that the first patient has been enrolled in the Company's U.S. clinical trial to evaluate the Ventanaa Fenestrated Stent Graft System for the endovascular repair of juxtarenal and pararenal abdominal aortic aneurysms .
Endologix (ELGX) Shares Upgraded by Zacks Investment Research to "Neutral"
Endologix was upgraded by Zacks Investment Research from an "underperform" rating to a "neutral" rating in a research note issued on Saturday.
Also on Topix